Question-and-Answer Session
Operator
(Operator Instructions). Our first question is from the Joshua Zable with Natixis. Your line is open.
Joshua Zable - Natixis
Hey guys, thank you very much for taking my questions and congrats on a great quarter here and a great outlook.
Walt Rosebrough
Thanks a lot, Josh.
Mike Tokich
Thanks Josh.
Joshua Zable - Natixis
I have a couple of quick question here, so let me get right to them. First, Walter I know you focused this past quarter on making sure the Monterrey stuff was going well, execution was happening. Can you just kind of tell us, I know you obviously talked about how far long you are, but just from here on until sort of everything is finished as far as execution goes what risks are out there?
I mean there is always risk, but may be just kind of give us sort of how confident you feel about this transition being completed having gone there and sort of now kind of fixed things up.
Walt Rosebrough
Talking specifically about Mexico?
Joshua Zable - Natixis
Yeah.
Walt Rosebrough
I am highly confident. Again, there is always risk in any operation but they are running as an operation should run, and in fact if anything we look forward to more improvements out of them.
Joshua Zable - Natixis
Great, okay, and just running down a line here, just in terms of the outlook just to be clear, obviously some headwinds in terms of materials and life science spending, I imagine, I know you addressed that and you also kind of mention potential for hospital spending slowing.
Can you just give us a little bit more color as far as your revenue guidance, what you are sort of factoring in, are you seeing any sort of slowdown today and sort of are you factoring it more in the later part of the year, is it sort of a general factor of your total overall guidance?
Walt Rosebrough
Sure. Two statements I guess. The first is on the Life science side, we have been discussing the fact that the pharma customers are pushing out projects overtime and have been out for probably six or eight months for better. And so that is a matter of fact and has influenced their order rates and again you see, they had a huge fourth quarter.
But that was largely shipping product that had been ordered year-over-year 18 months earlier kind of stuff. That probably over too much time with, certainly there had been order previously. We also saw a good return in the non-pharma piece of that business, so that went well.
- To read the full transcript on Seeking Alpha, click here »
